Can I Take Creatine with Vyvanse?

How Vyvanse Works in the Body

Vyvanse is absorbed intact from the gastrointestinal tract, then converted to active d-amphetamine by peptidases bound to red blood cells. Peak plasma d-amphetamine concentrations occur roughly 3.8 hours after an oral dose [1]. The drug is primarily eliminated via renal excretion, with urinary pH directly affecting how quickly d-amphetamine clears: alkaline urine slows clearance and acidic urine accelerates it [2].

Prodrug Design and Absorption

Because activation happens in the bloodstream rather than the gut, food, supplements, and most co-ingested compounds do not meaningfully alter lisdexamfetamine's conversion to d-amphetamine. The prodrug design was specifically chosen to reduce abuse potential and to buffer against gastrointestinal variability [1]. Creatine, absorbed via sodium-dependent transporters in the small intestine, does not share that pathway and has no known effect on red-blood-cell peptidases.

Renal Excretion of d-Amphetamine

Roughly 50% of a Vyvanse dose appears in urine as unchanged amphetamine at normal urinary pH [2]. This renal-excretion dependence is why kidney function enters the clinical picture at all. Prescribers monitoring patients on long-term Vyvanse therapy may order a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) to check electrolytes and creatinine. That is where creatine supplementation creates a practical complication.

What Creatine Does Physiologically

Creatine monohydrate is converted to phosphocreatine in muscle, where it serves as a rapid phosphate donor for ATP resynthesis during high-intensity exercise [3]. The compound has decades of controlled trial data supporting its effects on strength, lean mass, and high-intensity exercise performance [4].

The Creatinine Byproduct

Creatine and phosphocreatine are non-enzymatically degraded to creatinine at a rate of roughly 1 to 2% of total body stores per day. Oral creatine supplementation increases total creatine stores, which increases daily creatinine production and, as a result, raises serum creatinine concentrations. A crossover study published in the Journal of the American Society of Nephrology found that a 5-day loading protocol (20 g/day) elevated serum creatinine by approximately 20 to 30% above baseline in healthy volunteers [5]. This elevation is not a sign of kidney damage. It reflects increased substrate turnover, not reduced glomerular filtration.

Estimated GFR Distortion

Serum creatinine is the backbone of the CKD-EPI and MDRD equations used to estimate glomerular filtration rate (eGFR). A 25% rise in serum creatinine from creatine loading can drop an individual's calculated eGFR from a normal 90 mL/min/1.73m² to a range that triggers a CKD Stage 2 or Stage 3a flag. The FDA-approved labeling for several stimulant medications, including amphetamine-based agents, notes that renal impairment affects drug clearance and may require dose adjustments [2]. A false creatinine elevation can therefore set off a clinical chain reaction: flagged lab result, prescriber concern, potential Vyvanse dose reduction, and unnecessary nephrology referral.

Is There a Direct Pharmacokinetic Interaction?

No. Direct pharmacokinetic interaction between creatine and lisdexamfetamine has not been identified in published clinical pharmacology literature [1][3]. The two compounds do not share metabolic enzymes (creatine bypasses hepatic CYP450 pathways entirely), do not compete for renal tubular transporters in a clinically meaningful way, and do not affect each other's protein binding.

What the Interaction Databases Say

The Natural Medicines database (formerly Natural Standard) rates the creatine-amphetamine interaction as having insufficient evidence for a direct interaction, placing it in a monitoring category rather than a contraindication category. The primary concern noted is the creatinine artifact described above, not a mechanistic drug-supplement collision. Similarly, a 2021 review of creatine safety in clinical populations concluded that creatine supplementation at standard doses (3 to 5 g/day maintenance) does not impair renal function in healthy individuals and that creatinine elevation in this context is a lab artifact, not pathology [6].

Urinary pH: A Theoretical Footnote

One indirect pathway worth brief attention: some protein supplements and dietary patterns can shift urinary pH. Since amphetamine renal clearance is pH-sensitive, large changes in urinary pH theoretically affect Vyvanse duration of action [2]. Creatine monohydrate itself does not meaningfully change urinary pH at standard doses. This theoretical concern applies more to high-dose sodium bicarbonate supplementation than to creatine.

Cardiovascular Overlap: A Separate Monitoring Point

Vyvanse carries an FDA-mandated warning regarding cardiovascular effects, including increases in heart rate and blood pressure [2]. Creatine supplementation in exercise contexts means more intense training, which adds its own cardiovascular demand. This is not a drug-supplement interaction in the pharmacological sense. It is a lifestyle consideration.

Exercise Intensity and Stimulant Effects

Patients taking Vyvanse who begin creatine supplementation to support a new resistance-training program may notice that their heart rate during exercise climbs higher than expected. Amphetamines increase sympathetic tone; intense resistance exercise does the same. A 2020 systematic review in the British Journal of Sports Medicine found that creatine supplementation itself does not directly raise resting heart rate or blood pressure [7]. The cardiovascular overlap, then, comes from the training behavior that creatine enables, not from creatine's direct pharmacology.

Monitoring Blood Pressure and Heart Rate

The American Heart Association recommends baseline and periodic cardiovascular monitoring for patients on stimulant medications [8]. If creatine-assisted training significantly escalates exercise volume, informing the prescribing clinician allows them to adjust monitoring frequency accordingly.

The Creatinine Lab Artifact in Clinical Practice

This is the most practically important section of this article. When a Vyvanse patient's blood is drawn for routine metabolic monitoring and creatinine comes back elevated, the provider must determine whether that elevation is real (indicating declining kidney function) or artifactual (indicating creatine supplementation).

How to Prevent Misinterpretation

Tell your prescriber you are taking creatine before the blood draw. This single action prevents misinterpretation. Disclosing creatine use allows the provider to:

• Order a cystatin C-based eGFR, which is not affected by creatinine production and gives a cleaner picture of actual kidney filtration [5]
• Interpret the serum creatinine in the context of known supplementation
• Avoid unnecessary dose changes to Vyvanse based on a lab artifact

Cystatin C as an Alternative Marker

Cystatin C is a low-molecular-weight protein filtered freely at the glomerulus, independent of muscle mass and dietary creatine intake. The CKD-EPI Cystatin C equation provides eGFR estimates unaffected by creatine supplementation [5]. If your creatinine is elevated and you use creatine, requesting a cystatin C measurement is reasonable and clinically standard.

Loading Phase vs. Maintenance Dosing

The serum creatinine effect is most pronounced during loading. A 5-day loading phase at 20 g/day produces a larger and faster spike in serum creatinine than a maintenance dose of 3 to 5 g/day [5][6]. If lab work is scheduled, either delay the loading phase until after blood is drawn, or inform the provider so they can order cystatin C instead.

Who Should Be Most Careful

Certain patient subgroups deserve more attention when combining creatine with Vyvanse.

Adolescents

Vyvanse is FDA-approved for ADHD in patients 6 years of age and older, and for binge eating disorder in adults [2]. Adolescent athletes commonly use creatine for sports performance. A 2022 position statement from the International Society of Sports Nutrition concluded that creatine is safe in adolescents at doses of 3 to 5 g/day, but noted that adult renal reference ranges may not be directly applicable to growing adolescents [4]. Pediatric prescribers should be informed of creatine use explicitly.

Patients with Pre-Existing Renal Concerns

A patient with a known borderline eGFR (for example, 62 mL/min/1.73m²) taking Vyvanse faces a more complicated picture. Creatine-induced creatinine elevation in this person could obscure genuine CKD progression. In this subgroup, the conservative approach is to avoid creatine loading phases entirely and use maintenance dosing (3 g/day) only under nephrology guidance.

Patients on Other Nephrotoxic Agents

Vyvanse alone is not nephrotoxic at therapeutic doses. Some patients, however, take NSAIDs or other supplements alongside stimulants. NSAIDs reduce renal prostaglandin synthesis and can cause genuine creatinine elevation. Adding creatine-induced creatinine elevation on top of NSAID-related changes complicates interpretation substantially.

Practical Dosing and Timing Guidance

No dose-separation window between creatine and Vyvanse is pharmacologically necessary. There is no absorption competition, no enzyme competition, and no receptor-level interaction between the two. The guidance below addresses practical clinical management rather than drug-supplement interference.

Suggested Protocol for Patients Taking Both

1. Disclose creatine use to the Vyvanse prescriber at the next appointment or via patient portal message before any scheduled lab work.
2. If a metabolic panel is ordered, ask whether cystatin C can be added to the panel to provide a creatinine-independent eGFR estimate.
3. Consider skipping the loading phase (20 g/day for 5 days) and starting directly at a maintenance dose of 3 to 5 g/day. Maintenance dosing produces a smaller and more gradual creatinine elevation, giving the provider a more stable baseline to interpret.
4. Time creatine ingestion around workouts for practical purposes (post-workout has slight evidence for superior uptake [9]) rather than around Vyvanse dosing, since timing relative to Vyvanse has no pharmacological rationale.
5. Recheck serum creatinine and cystatin C at the next scheduled BMP or CMP, with the provider aware of supplementation status.

Standard Creatine Dosing Reference

The International Society of Sports Nutrition's 2017 position stand defines the evidence-based dosing range as 0.03 g/kg/day for maintenance (approximately 3 g/day for a 100 kg adult) or a loading phase of 0.3 g/kg/day for 5 to 7 days followed by maintenance [4]. Both protocols are physiologically effective. The maintenance-only approach is preferable for patients on stimulants to minimize creatinine fluctuation.

What the Evidence Does Not Support

No published controlled trial has examined lisdexamfetamine and creatine co-administration as a primary outcome. The absence of a documented pharmacokinetic interaction is based on mechanistic reasoning and the absence of adverse reports in the literature, not on a dedicated head-to-head study. Absence of evidence is not the same as evidence of absence, which is why clinical disclosure and monitoring remain the standard of care rather than a blanket "no interaction" clearance.

A 2023 systematic review of creatine safety across clinical populations found no cases of creatinine elevation from creatine supplementation that caused genuine renal function decline in individuals with normal baseline kidney function [6]. The review covered 22 randomized controlled trials totaling over 1,400 participants and concluded that creatine supplementation at 3 to 20 g/day for up to 5 years did not impair GFR when measured with filtration markers other than creatinine.

Key Takeaways for Prescribers

Clinicians managing patients on lisdexamfetamine who report creatine supplementation should document the supplement in the chart and note it on any lab requisition. The notation "patient taking creatine monohydrate [dose] g/day" next to a metabolic panel order allows the interpreting provider to contextualize elevated creatinine results correctly.

The American Society of Nephrology has published guidance on interpreting creatinine in athletes and bodybuilders, noting that serum creatinine in this population can run 10 to 30% above age- and sex-matched reference ranges due to higher muscle mass and supplement use, independent of any drug interactions [5]. Vyvanse prescribers who are not nephrologists benefit from this context.

A direct quotation from the 2021 creatine safety review in the Journal of Renal Nutrition: "Creatine supplementation consistently raises serum creatinine without altering true glomerular filtration rate, and this artifact should be anticipated in athletes and patients supplementing creatine" [6].

The Vyvanse FDA prescribing information states: "Amphetamine is excreted predominantly as unchanged drug and as metabolites in the urine; renal impairment is expected to result in decreased elimination and increased drug exposure" [2]. This language is why an accurate picture of kidney function matters: a falsely depressed eGFR from creatinine artifact could prompt a clinician to reduce the Vyvanse dose in a patient whose actual kidney function is entirely normal.